AstraZeneca has filed for FDA approval of savolitinib plus Tagrisso for EGFR-mutated lung cancer with MET-driven resistance. Full SAFFRON data are pending.
AstraZeneca Seeks FDA Approval for Savolitinib Plus Tagrisso in Lung Cancer That Resists Tagrisso Through MET Changes
by | Oct 1, 2026 | Uncategorized | 0 comments
Recent Comments